万赛维有耐药性吗？

The main ingredient of the tablet is valganciclovir hydrochloride, which was developed by the Swiss company Roche and is an oral anti-cytomegalovirus infection drug. In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients. On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. Launched in China in 2006, it is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

Is there resistance to Vancevir, an anti-cytomegalovirus infection drug?

Patients will develop resistance to any drug after taking it for a certain period of time, and Vancevi is no exception. However, because each patient's constitution and disease progression are different, the time and performance of drug resistance are also different for each patient. When a patient develops drug resistance, he should consult the relevant doctor as soon as possible to change or replace the treatment plan.

Precautions: Hematological disorders: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia and bone marrow failure, including aplastic anemia. May occur at any time during treatment and worsen with continued use; cell counts usually begin to recover within 3-7 days of stopping treatment. Do not use if the absolute neutrophil count is <500 cells/MM3, platelet count <25,000/m3, or hemoglobin <8 g/dl; use with caution in patients with myelosuppression, cytopenia, or patients receiving myelosuppressive drugs/radiation. Monitor CBC and platelet counts at baseline and frequently during treatment, especially in infants and patients with renal impairment, patients with prior drug-induced leukopenia, and patients with neutrophil counts <1000 cells/mm3 at the start of treatment. Carcinogenicity/Teratogenicity: May temporarily or permanently inhibit spermatogenesis and suppress fertility; may cause birth defects and cancer in humans. Due to its teratogenicity, women should take a pregnancy test before initiating pregnancy and use effective contraception during treatment and for 30 days after treatment; men should use barrier contraception during treatment and for 90 days after treatment.